PDF(Pubmed)
Abstract：
BACKGROUND: Breast cancer treatment is multimodal, but not all patients benefit from each treatment, and many experience morbidities significantly impacting quality of life. There is increasing interest in tailoring breast cancer treatments to optimize oncological outcomes and reduce treatment burden, but it is vital that future trials focus on treatments that most impact patients. This study was designed to explore patient experiences of treatment to inform future research.
METHODS: An online survey was co-developed with patient advocates to explore respondents\' experiences of breast cancer treatment. Questions included simple demographics, treatments received, and views regarding omitting treatments if that is deemed safe. The survey was circulated via social media and patient advocacy groups. Responses were summarized by using simple statistics; free text was analyzed thematically.
RESULTS: Of the 235 participants completing the survey, 194 (82.6%) would choose to omit a specific treatment if safe to do so. The most commonly selected treatments were chemotherapy (n = 69, 35.6%) and endocrine therapy (n = 61, 31.4%) mainly due to side effects. Fewer respondents would choose to omit surgery (n = 40, 20.6%) or radiotherapy (n = 20, 10.3%). Several women commented that survival was their \"absolute priority\" and that high-quality evidence to support the safety of reducing treatment would be essential.
CONCLUSIONS: Patients with breast cancer are individuals who may wish to optimize different components of their treatment. A portfolio of studies co-designed with patients is needed to establish an evidence base for greater treatment personalization with studies focused on reducing avoidable chemotherapy and endocrine therapy a priority.
METHODS: An online survey was co-developed with patient advocates to explore respondents\' experiences of breast cancer treatment. Questions included simple demographics, treatments received, and views regarding omitting treatments if that is deemed safe. The survey was circulated via social media and patient advocacy groups. Responses were summarized by using simple statistics; free text was analyzed thematically.
RESULTS: Of the 235 participants completing the survey, 194 (82.6%) would choose to omit a specific treatment if safe to do so. The most commonly selected treatments were chemotherapy (n = 69, 35.6%) and endocrine therapy (n = 61, 31.4%) mainly due to side effects. Fewer respondents would choose to omit surgery (n = 40, 20.6%) or radiotherapy (n = 20, 10.3%). Several women commented that survival was their \"absolute priority\" and that high-quality evidence to support the safety of reducing treatment would be essential.
CONCLUSIONS: Patients with breast cancer are individuals who may wish to optimize different components of their treatment. A portfolio of studies co-designed with patients is needed to establish an evidence base for greater treatment personalization with studies focused on reducing avoidable chemotherapy and endocrine therapy a priority.
摘要：
背景：乳腺癌治疗是多模式的，但并非所有患者都能从每种治疗中受益，和许多经验的发病率显着影响生活质量。人们对定制乳腺癌治疗以优化肿瘤学结果并减轻治疗负担的兴趣日益增加。但至关重要的是，未来的试验将重点放在对患者影响最大的治疗方法上。这项研究旨在探索患者的治疗经验，为未来的研究提供信息。
方法：与患者倡导者共同开发了一项在线调查，以探索受访者对乳腺癌治疗的经验。问题包括简单的人口统计，接受治疗,以及关于在认为安全的情况下省略治疗的意见。该调查通过社交媒体和患者倡导团体分发。通过使用简单的统计数据来总结响应；对自由文本进行主题分析。
结果：在完成调查的235名参与者中，如果安全的话，194（82.6％）会选择省略特定的治疗方法。最常选择的治疗方法是化疗（n=69，35.6%）和内分泌治疗（n=61，31.4%），主要是由于副作用。更少的受访者会选择省略手术（n=40，20.6%）或放疗（n=20，10.3%）。几位妇女评论说，生存是他们的“绝对优先”，高质量的证据来支持减少治疗的安全性将是必不可少的。
结论：乳腺癌患者是可能希望优化其治疗的不同组成部分的个体。需要与患者共同设计的研究组合，以建立更多个性化治疗的证据基础，重点是减少可避免的化疗和内分泌治疗的研究。
方法：与患者倡导者共同开发了一项在线调查，以探索受访者对乳腺癌治疗的经验。问题包括简单的人口统计，接受治疗,以及关于在认为安全的情况下省略治疗的意见。该调查通过社交媒体和患者倡导团体分发。通过使用简单的统计数据来总结响应；对自由文本进行主题分析。
结果：在完成调查的235名参与者中，如果安全的话，194（82.6％）会选择省略特定的治疗方法。最常选择的治疗方法是化疗（n=69，35.6%）和内分泌治疗（n=61，31.4%），主要是由于副作用。更少的受访者会选择省略手术（n=40，20.6%）或放疗（n=20，10.3%）。几位妇女评论说，生存是他们的“绝对优先”，高质量的证据来支持减少治疗的安全性将是必不可少的。
结论：乳腺癌患者是可能希望优化其治疗的不同组成部分的个体。需要与患者共同设计的研究组合，以建立更多个性化治疗的证据基础，重点是减少可避免的化疗和内分泌治疗的研究。
